Tuen Mun Hospital, Hong Kong   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Hong Kong Hong Kong (1990)

Organization Overview

First Clinical Trial
2002
NCT00636103
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Department of Medicine, Tuen Mun Hospital, Hong Kong | Medical and Geriatrics / Nephrology, Tuen Mun Hospital | Tuen Mun Hospital | Tuen Mun Hospital Hong Kong | Tuen Mun Hospital, Hong Kong China | Tuen Mun Hospital, Hong Kong, China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Asthma (Phase 2)

Atherosclerosis (Phase 4)

Cachexia (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Emergencies (Phase 4)

Lupus Erythematosus, Systemic (Phase 4)

Lupus Nephritis (Phase 4)

Nephritis (Phase 4)

Osteoporosis (Phase 4)

Psychomotor Agitation (Phase 4)

Spondylarthritis (Phase 4)

Spondylarthropathies (Phase 4)

Thromboembolism (Phase 4)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 27